Cybin appoints Cola CEO

Executive Summary

• Cybin Inc., doing business as Helus Pharma, has appointed Michael Cola as its new Chief Executive Officer, effective immediately.
• The appointment coincides with a pivotal phase in the company's development pipeline, specifically targeting key clinical milestones including Phase 2 data for HLP004 expected this quarter and Phase 3 top-line data for HLP003 in Q4 2026.
• CEO Eric So highlights Cola’s background in neuroscience, commercialization, and capital markets as critical for leading the company’s transition from early clinical development to later-stage execution and global scale-up.

Key Details

• Appointment: Michael Cola appointed as Chief Executive Officer of Helus Pharma (Cybin Inc.), effective immediately.
• Pipeline Milestones:
  • Expected release of Phase 2 data for HLP004 this quarter.
  • Expected Phase 3 top-line data for HLP003 in the fourth quarter of 2026.
• Intellectual Property: The company has filed more than 350 patent applications globally and has over 100 patents granted.
• Strategic Focus: The company is shifting focus toward global regulatory engagement and long-term commercial planning as it moves from early clinical development to later-stage execution.
• CEO Background: Michael Cola has over 30 years of experience in neuroscience, rare disease, and specialty pharmaceuticals, with senior leadership roles in R&D, commercialization, corporate strategy, and capital formation.
• CEO Education: Bachelor’s degree in biology from Ursinus College; Master of Science in biomedical science and engineering from Drexel University; studied bioengineering at the University of Pennsylvania.

Notable Quotes

• Eric So, Co-founder and Executive Chairman: "Michael brings a rare combination of deep neuroscience expertise, global commercialization experience and proven capital markets leadership... his track record of building first-in-class CNS franchises and scaling global organizations makes him uniquely suited to lead Helus as we work to translate our science into meaningful therapies for patients and long-term value for shareholders."
• Michael Cola, CEO: "I am honoured to join Helus at a pivotal and energizing moment... With highly differentiated HLP003 clinical data already in hand and a robust pipeline of novel compounds in development, Helus is uniquely positioned to advance a new paradigm in the treatment of serious mental health disorders."